Radiolabeled Triazole Conjugated Ureas (YC-88)

Case ID:

C13079

Disclosure Date:

5/14/2014

Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease. PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic, renal carcinoma and skin melanoma, but not in normal vasculature, which makes it an excellent target for imaging and targeted therapy of these cancers. Here we describe a series of PSMA-targeted radiolabeled triazole conjugated ureas developed through click chemistry.

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Radiolabeled Triazole Conjugated Ureas	PCT: Patent Cooperation Treaty	United States	15/752,340	11,078,166	2/13/2018	8/3/2021	12/11/2036	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/24732

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics > Diagnostic Imaging,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Jeanine Pennington

jpennin5@jhmi.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF